Share Price and Basic Stock Data
Last Updated: December 11, 2025, 10:16 pm
| PEG Ratio | 3.27 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Acutaas Chemicals Ltd operates within the pharmaceuticals sector, a space marked by both growth potential and competitive challenges. The company’s revenue trajectory has shown a commendable upward trend, with sales rising from ₹520 Cr in FY 2022 to ₹1,007 Cr in FY 2025, marking a significant increase in demand for its products. The latest trailing twelve months (TTM) figure stood at ₹1,037 Cr, reflecting robust sales momentum. Quarterly performance also highlights this growth; for example, revenue surged to ₹225 Cr in Q4 FY 2024 and further to ₹308 Cr in Q1 FY 2025, suggesting strong operational execution. However, the top line isn’t without its fluctuations, such as a dip to ₹154 Cr in Q2 FY 2023, indicating some volatility that could concern investors. Overall, the revenue growth appears strong, driven by strategic positioning within a growing market.
Profitability and Efficiency Metrics
Acutaas Chemicals has demonstrated impressive profitability metrics, with a net profit of ₹190 Cr for TTM, a significant leap from ₹83 Cr in FY 2023. The operating profit margin (OPM) stood at 25%, reflecting efficient cost management relative to its sales. The company’s P/E ratio of 60.4 might seem stretched compared to industry norms, but it is indicative of investor confidence in future earnings potential. Additionally, the interest coverage ratio (ICR) at 40.04x underscores the company’s ability to comfortably meet its interest obligations, a reassuring sign for stakeholders. However, the reported dip in OPM to 14% in Q3 FY 2023 raises questions about the sustainability of margins amid rising costs. Investors should keep an eye on these efficiency metrics, as they are critical for assessing long-term profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Acutaas Chemicals appears solid, with total borrowings remarkably low at ₹8 Cr, showcasing a conservative debt strategy that minimizes financial risk. The company holds reserves of ₹1,373 Cr, which provides a cushion for future investments or downturns. Its current ratio of 3.91 suggests a healthy liquidity position, enabling it to cover short-term liabilities comfortably. However, the price-to-book value (P/BV) ratio of 15.26x indicates that the stock may be overvalued relative to its book value, which could pose a risk if market sentiments shift. Furthermore, the return on equity (ROE) at 16% and return on capital employed (ROCE) at 19.9% signal effective utilization of shareholders’ funds, but investors should remain cautious of maintaining these levels in a competitive landscape.
Shareholding Pattern and Investor Confidence
Acutaas Chemicals’ shareholding structure reveals a diverse ownership landscape, with promoters holding 32.66% and institutional investors (FIIs and DIIs) constituting approximately 39.43% of total holdings. This mix suggests a healthy level of institutional interest, which often reflects confidence in a company’s prospects. Notably, the increase in FII ownership from 6.41% in December 2022 to 16.84% by September 2025 highlights growing foreign investor confidence. Conversely, the decline in promoter holdings from over 39% to 32.66% raises some flags about insider confidence. The public holds nearly 27.89%, indicating a broad base of retail investors. Such a diverse shareholder base can be a double-edged sword; while it reflects confidence, any significant selling by major stakeholders could impact stock prices adversely.
Outlook, Risks, and Final Insight
Looking ahead, Acutaas Chemicals is well-positioned in a growing pharmaceuticals market, but several risks could temper investor enthusiasm. The company’s historical revenue fluctuations may point to potential instability in sales, particularly in light of external factors like regulatory changes or supply chain disruptions. Additionally, while the balance sheet is strong now, any future borrowing could shift perceptions, particularly in a rising interest rate environment. Investors should also watch the margins closely; the recent dip in operational efficiency raises concerns about cost management. Overall, while the fundamentals of Acutaas Chemicals seem robust, particularly with its strong profitability ratios and healthy balance sheet, the company must navigate these risks carefully to sustain growth. Investors might consider a cautious stance, weighing the company’s strengths against these potential vulnerabilities as they make decisions on this stock.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Acutaas Chemicals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,260 Cr. | 390 | 479/192 | 88.2 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,465.89 Cr | 1,157.79 | 52.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131 | 147 | 152 | 186 | 154 | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 |
| Expenses | 108 | 119 | 122 | 146 | 120 | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 |
| Operating Profit | 23 | 28 | 31 | 41 | 34 | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 |
| OPM % | 17% | 19% | 20% | 22% | 22% | 14% | 16% | 19% | 17% | 20% | 25% | 28% | 25% |
| Other Income | 1 | 1 | 3 | -0 | 1 | -30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 |
| Profit before tax | 20 | 26 | 30 | 37 | 31 | -10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 |
| Tax % | 27% | 26% | 25% | 26% | 28% | 71% | 25% | 31% | 26% | 25% | 28% | 24% | 24% |
| Net Profit | 15 | 19 | 22 | 27 | 22 | -17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 |
| EPS in Rs | 2.04 | 2.61 | 3.06 | 3.73 | 2.71 | -2.55 | 2.27 | 3.41 | 1.71 | 4.56 | 5.49 | 7.63 | 5.41 |
Last Updated: August 9, 2025, 11:12 am
Below is a detailed analysis of the quarterly data for Acutaas Chemicals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 207.00 Cr.. The value appears to be declining and may need further review. It has decreased from 308.00 Cr. (Mar 2025) to 207.00 Cr., marking a decrease of 101.00 Cr..
- For Expenses, as of Jun 2025, the value is 156.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 224.00 Cr. (Mar 2025) to 156.00 Cr., marking a decrease of 68.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 51.00 Cr.. The value appears to be declining and may need further review. It has decreased from 85.00 Cr. (Mar 2025) to 51.00 Cr., marking a decrease of 34.00 Cr..
- For OPM %, as of Jun 2025, the value is 25.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Mar 2025) to 25.00%, marking a decrease of 3.00%.
- For Other Income, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 10.00 Cr..
- For Interest, as of Jun 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 8.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 83.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 25.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00%.
- For Net Profit, as of Jun 2025, the value is 44.00 Cr.. The value appears to be declining and may need further review. It has decreased from 63.00 Cr. (Mar 2025) to 44.00 Cr., marking a decrease of 19.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 5.41. The value appears to be declining and may need further review. It has decreased from 7.63 (Mar 2025) to 5.41, marking a decrease of 2.22.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 9, 2025, 11:12 am
| Metric | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 188 | 239 | 240 | 341 | 520 | 617 | 717 | 1,007 | 1,037 |
| Expenses | 137 | 157 | 196 | 198 | 260 | 415 | 493 | 589 | 775 | 784 |
| Operating Profit | 23 | 31 | 42 | 42 | 80 | 105 | 123 | 128 | 232 | 253 |
| OPM % | 14% | 16% | 18% | 17% | 24% | 20% | 20% | 18% | 23% | 24% |
| Other Income | 0 | 3 | 0 | 2 | 1 | 3 | 4 | -25 | 17 | 32 |
| Interest | 3 | 3 | 5 | 6 | 6 | 6 | 2 | 6 | 6 | 2 |
| Depreciation | 1 | 2 | 3 | 4 | 4 | 10 | 12 | 16 | 27 | 29 |
| Profit before tax | 19 | 28 | 35 | 35 | 72 | 91 | 112 | 82 | 216 | 254 |
| Tax % | 35% | 35% | 34% | 21% | 25% | 21% | 26% | 41% | 26% | |
| Net Profit | 12 | 18 | 23 | 27 | 54 | 72 | 83 | 49 | 160 | 190 |
| EPS in Rs | 40.17 | 61.67 | 11.10 | 13.08 | 8.57 | 9.87 | 11.43 | 5.80 | 19.38 | 23.09 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 15% | 13% | 26% | 8% |
YoY Net Profit Growth
| Year | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | 27.78% | 17.39% | 100.00% | 33.33% | 15.28% | -40.96% | 226.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -22.22% | -10.39% | 82.61% | -66.67% | -18.06% | -56.24% | 267.49% |
Acutaas Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 33% |
| 3 Years: | 25% |
| TTM: | 40% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 41% |
| 3 Years: | 30% |
| TTM: | 205% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 39% |
| 1 Year: | 97% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 14% |
| Last Year: | 16% |
Last Updated: September 5, 2025, 2:16 pm
Balance Sheet
Last Updated: December 4, 2025, 2:21 am
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 10 | 10 | 32 | 36 | 36 | 37 | 41 | 41 |
| Reserves | 37 | 56 | 72 | 101 | 135 | 486 | 558 | 637 | 1,269 | 1,373 |
| Borrowings | 27 | 44 | 54 | 59 | 137 | 1 | 4 | 217 | 13 | 8 |
| Other Liabilities | 43 | 54 | 77 | 61 | 110 | 136 | 169 | 205 | 227 | 274 |
| Total Liabilities | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,696 |
| Fixed Assets | 28 | 32 | 79 | 85 | 186 | 205 | 259 | 427 | 570 | 700 |
| CWIP | 11 | 30 | 2 | 12 | 0 | 3 | 30 | 125 | 130 | 152 |
| Investments | 1 | 3 | 2 | 2 | 1 | 2 | 2 | 0 | 0 | 0 |
| Other Assets | 68 | 91 | 131 | 133 | 225 | 450 | 477 | 543 | 848 | 843 |
| Total Assets | 109 | 155 | 213 | 232 | 413 | 659 | 767 | 1,096 | 1,549 | 1,696 |
Below is a detailed analysis of the balance sheet data for Acutaas Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 41.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 41.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,373.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,269.00 Cr. (Mar 2025) to 1,373.00 Cr., marking an increase of 104.00 Cr..
- For Borrowings, as of Sep 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 274.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 227.00 Cr. (Mar 2025) to 274.00 Cr., marking an increase of 47.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,696.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,549.00 Cr. (Mar 2025) to 1,696.00 Cr., marking an increase of 147.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 700.00 Cr.. The value appears strong and on an upward trend. It has increased from 570.00 Cr. (Mar 2025) to 700.00 Cr., marking an increase of 130.00 Cr..
- For CWIP, as of Sep 2025, the value is 152.00 Cr.. The value appears strong and on an upward trend. It has increased from 130.00 Cr. (Mar 2025) to 152.00 Cr., marking an increase of 22.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 843.00 Cr.. The value appears to be declining and may need further review. It has decreased from 848.00 Cr. (Mar 2025) to 843.00 Cr., marking a decrease of 5.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,696.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,549.00 Cr. (Mar 2025) to 1,696.00 Cr., marking an increase of 147.00 Cr..
Notably, the Reserves (1,373.00 Cr.) exceed the Borrowings (8.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -4.00 | -13.00 | -12.00 | -17.00 | -57.00 | 104.00 | 119.00 | -89.00 | 219.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 83 | 97 | 116 | 86 | 129 | 115 | 136 | 105 | 105 |
| Inventory Days | 76 | 89 | 95 | 148 | 123 | 150 | 131 | 139 | 119 |
| Days Payable | 148 | 154 | 168 | 146 | 172 | 158 | 157 | 119 | 103 |
| Cash Conversion Cycle | 11 | 31 | 43 | 88 | 80 | 107 | 111 | 125 | 121 |
| Working Capital Days | 46 | 64 | 28 | 34 | 51 | 141 | 139 | 79 | 123 |
| ROCE % | 38% | 34% | 27% | 33% | 24% | 21% | 16% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Large & Midcap Fund | 2,000,000 | 0.97 | 345.54 | 2,275,837 | 2025-11-02 14:30:42 | -12.12% |
| Kotak Multicap Fund | 1,366,139 | 1.1 | 236.03 | N/A | N/A | N/A |
| SBI Healthcare Opportunities Fund | 900,000 | 3.81 | 155.49 | 1,000,000 | 2025-11-02 14:30:42 | -10% |
| UTI Small Cap Fund | 524,144 | 1.84 | 90.56 | 592,983 | 2025-11-02 14:30:42 | -11.61% |
| ITI Small Cap Fund | 453,450 | 2.76 | 78.34 | 446,344 | 2025-11-02 14:30:42 | 1.59% |
| Tata ELSS Fund | 434,420 | 1.59 | 75.05 | N/A | N/A | N/A |
| Kotak Balanced Advantage Fund | 390,000 | 0.38 | 67.38 | N/A | N/A | N/A |
| Bank of India Small Cap Fund | 373,610 | 3.2 | 64.55 | 375,142 | 2025-11-02 14:30:42 | -0.41% |
| Union Small Cap Fund | 360,154 | 3.48 | 62.22 | 350,154 | 2025-11-02 14:30:42 | 2.86% |
| Bank of India Flexi Cap Fund | 329,922 | 2.52 | 57 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 5.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.81 | 11.67 | 22.86 | 21.03 | 17.14 |
| Diluted EPS (Rs.) | 19.81 | 11.66 | 22.86 | 21.03 | 17.14 |
| Cash EPS (Rs.) | 22.85 | 17.56 | 26.25 | 22.51 | 18.47 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 159.97 | 185.13 | 163.01 | 143.34 | 52.99 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 159.97 | 185.13 | 163.01 | 143.34 | 52.99 |
| Revenue From Operations / Share (Rs.) | 122.99 | 194.54 | 169.26 | 142.75 | 108.13 |
| PBDIT / Share (Rs.) | 30.41 | 36.87 | 34.83 | 29.62 | 25.88 |
| PBIT / Share (Rs.) | 27.16 | 32.52 | 31.45 | 26.86 | 24.55 |
| PBT / Share (Rs.) | 26.40 | 22.21 | 30.79 | 25.10 | 22.77 |
| Net Profit / Share (Rs.) | 19.59 | 13.21 | 22.86 | 19.75 | 17.14 |
| NP After MI And SOA / Share (Rs.) | 19.39 | 11.60 | 22.86 | 19.75 | 17.14 |
| PBDIT Margin (%) | 24.73 | 18.95 | 20.58 | 20.75 | 23.93 |
| PBIT Margin (%) | 22.08 | 16.71 | 18.57 | 18.81 | 22.70 |
| PBT Margin (%) | 21.46 | 11.41 | 18.18 | 17.58 | 21.05 |
| Net Profit Margin (%) | 15.93 | 6.78 | 13.50 | 13.83 | 15.85 |
| NP After MI And SOA Margin (%) | 15.76 | 5.96 | 13.50 | 13.83 | 15.85 |
| Return on Networth / Equity (%) | 12.11 | 6.34 | 14.02 | 13.77 | 32.34 |
| Return on Capital Employeed (%) | 16.50 | 14.79 | 18.96 | 18.47 | 31.28 |
| Return On Assets (%) | 10.24 | 3.90 | 10.86 | 10.91 | 13.06 |
| Long Term Debt / Equity (X) | 0.00 | 0.16 | 0.00 | 0.00 | 0.43 |
| Total Debt / Equity (X) | 0.01 | 0.32 | 0.01 | 0.00 | 0.70 |
| Asset Turnover Ratio (%) | 0.76 | 0.77 | 0.86 | 0.97 | 1.06 |
| Current Ratio (X) | 3.91 | 1.74 | 2.89 | 3.32 | 1.30 |
| Quick Ratio (X) | 3.02 | 1.19 | 2.15 | 2.45 | 0.93 |
| Inventory Turnover Ratio (X) | 5.98 | 3.19 | 2.99 | 3.27 | 3.10 |
| Dividend Payout Ratio (NP) (%) | 7.73 | 25.55 | 13.12 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.62 | 18.58 | 11.43 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 92.27 | 74.45 | 86.88 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.38 | 81.42 | 88.57 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 40.04 | 22.89 | 52.62 | 16.85 | 14.51 |
| Interest Coverage Ratio (Post Tax) (X) | 26.80 | 14.60 | 35.53 | 12.23 | 10.61 |
| Enterprise Value (Cr.) | 19758.43 | 4208.12 | 3184.01 | 3543.73 | 0.00 |
| EV / Net Operating Revenue (X) | 19.62 | 5.87 | 5.16 | 6.81 | 0.00 |
| EV / EBITDA (X) | 79.35 | 30.95 | 25.09 | 32.83 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 19.85 | 5.63 | 5.25 | 7.00 | 0.00 |
| Retention Ratios (%) | 92.26 | 74.44 | 86.87 | 0.00 | 0.00 |
| Price / BV (X) | 15.26 | 5.99 | 5.45 | 6.97 | 0.00 |
| Price / Net Operating Revenue (X) | 19.85 | 5.63 | 5.25 | 7.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 |
After reviewing the key financial ratios for Acutaas Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 5.00. This value is within the healthy range. It has decreased from 10.00 (Mar 24) to 5.00, marking a decrease of 5.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.81. This value is within the healthy range. It has increased from 11.67 (Mar 24) to 19.81, marking an increase of 8.14.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.81. This value is within the healthy range. It has increased from 11.66 (Mar 24) to 19.81, marking an increase of 8.15.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.85. This value is within the healthy range. It has increased from 17.56 (Mar 24) to 22.85, marking an increase of 5.29.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 159.97. It has decreased from 185.13 (Mar 24) to 159.97, marking a decrease of 25.16.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 159.97. It has decreased from 185.13 (Mar 24) to 159.97, marking a decrease of 25.16.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 122.99. It has decreased from 194.54 (Mar 24) to 122.99, marking a decrease of 71.55.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 30.41. This value is within the healthy range. It has decreased from 36.87 (Mar 24) to 30.41, marking a decrease of 6.46.
- For PBIT / Share (Rs.), as of Mar 25, the value is 27.16. This value is within the healthy range. It has decreased from 32.52 (Mar 24) to 27.16, marking a decrease of 5.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 26.40. This value is within the healthy range. It has increased from 22.21 (Mar 24) to 26.40, marking an increase of 4.19.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 19.59. This value is within the healthy range. It has increased from 13.21 (Mar 24) to 19.59, marking an increase of 6.38.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 19.39. This value is within the healthy range. It has increased from 11.60 (Mar 24) to 19.39, marking an increase of 7.79.
- For PBDIT Margin (%), as of Mar 25, the value is 24.73. This value is within the healthy range. It has increased from 18.95 (Mar 24) to 24.73, marking an increase of 5.78.
- For PBIT Margin (%), as of Mar 25, the value is 22.08. This value exceeds the healthy maximum of 20. It has increased from 16.71 (Mar 24) to 22.08, marking an increase of 5.37.
- For PBT Margin (%), as of Mar 25, the value is 21.46. This value is within the healthy range. It has increased from 11.41 (Mar 24) to 21.46, marking an increase of 10.05.
- For Net Profit Margin (%), as of Mar 25, the value is 15.93. This value exceeds the healthy maximum of 10. It has increased from 6.78 (Mar 24) to 15.93, marking an increase of 9.15.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 5.96 (Mar 24) to 15.76, marking an increase of 9.80.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.11. This value is below the healthy minimum of 15. It has increased from 6.34 (Mar 24) to 12.11, marking an increase of 5.77.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.50. This value is within the healthy range. It has increased from 14.79 (Mar 24) to 16.50, marking an increase of 1.71.
- For Return On Assets (%), as of Mar 25, the value is 10.24. This value is within the healthy range. It has increased from 3.90 (Mar 24) to 10.24, marking an increase of 6.34.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.16 (Mar 24) to 0.00, marking a decrease of 0.16.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.32 (Mar 24) to 0.01, marking a decrease of 0.31.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.76. It has decreased from 0.77 (Mar 24) to 0.76, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.91. This value exceeds the healthy maximum of 3. It has increased from 1.74 (Mar 24) to 3.91, marking an increase of 2.17.
- For Quick Ratio (X), as of Mar 25, the value is 3.02. This value exceeds the healthy maximum of 2. It has increased from 1.19 (Mar 24) to 3.02, marking an increase of 1.83.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.98. This value is within the healthy range. It has increased from 3.19 (Mar 24) to 5.98, marking an increase of 2.79.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.73. This value is below the healthy minimum of 20. It has decreased from 25.55 (Mar 24) to 7.73, marking a decrease of 17.82.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.62. This value is below the healthy minimum of 20. It has decreased from 18.58 (Mar 24) to 6.62, marking a decrease of 11.96.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.27. This value exceeds the healthy maximum of 70. It has increased from 74.45 (Mar 24) to 92.27, marking an increase of 17.82.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.38. This value exceeds the healthy maximum of 70. It has increased from 81.42 (Mar 24) to 93.38, marking an increase of 11.96.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 40.04. This value is within the healthy range. It has increased from 22.89 (Mar 24) to 40.04, marking an increase of 17.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 26.80. This value is within the healthy range. It has increased from 14.60 (Mar 24) to 26.80, marking an increase of 12.20.
- For Enterprise Value (Cr.), as of Mar 25, the value is 19,758.43. It has increased from 4,208.12 (Mar 24) to 19,758.43, marking an increase of 15,550.31.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 19.62. This value exceeds the healthy maximum of 3. It has increased from 5.87 (Mar 24) to 19.62, marking an increase of 13.75.
- For EV / EBITDA (X), as of Mar 25, the value is 79.35. This value exceeds the healthy maximum of 15. It has increased from 30.95 (Mar 24) to 79.35, marking an increase of 48.40.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 19.85. This value exceeds the healthy maximum of 3. It has increased from 5.63 (Mar 24) to 19.85, marking an increase of 14.22.
- For Retention Ratios (%), as of Mar 25, the value is 92.26. This value exceeds the healthy maximum of 70. It has increased from 74.44 (Mar 24) to 92.26, marking an increase of 17.82.
- For Price / BV (X), as of Mar 25, the value is 15.26. This value exceeds the healthy maximum of 3. It has increased from 5.99 (Mar 24) to 15.26, marking an increase of 9.27.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 19.85. This value exceeds the healthy maximum of 3. It has increased from 5.63 (Mar 24) to 19.85, marking an increase of 14.22.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Acutaas Chemicals Ltd:
- Net Profit Margin: 15.93%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.5% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.11% (Industry Average ROE: 14.71%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 26.8
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.02
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 60.6 (Industry average Stock P/E: 43.24)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.93%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 440/4, 5 & 6, Surat Gujarat 394230 | investorinfo@amiorganics.com http://www.amiorganics.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Nareshkumar Ramjibhai Patel | Exe.Chairman & Mng.Director |
| Mr. Virendra Nath Mishra | Whole Time Director |
| Mr. Ram Mohan Rao Locande | Whole Time Director |
| Mr. Chetankumar Chhaganlal Vaghasia | Whole Time Director |
| Mr. Hetal Madhukant Gandhi | Independent Director |
| Mr. Girikrishna Suryakant Maniar | Independent Director |
| Mrs. Richa Manoj Goyal | Independent Director |
| Dr. Anita Bandyopadhyay | Independent Director |
FAQ
What is the intrinsic value of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd's intrinsic value (as of 11 December 2025) is 1343.13 which is 19.09% lower the current market price of 1,660.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 13,568 Cr. market cap, FY2025-2026 high/low of 1,902/919, reserves of ₹1,373 Cr, and liabilities of 1,696 Cr.
What is the Market Cap of Acutaas Chemicals Ltd?
The Market Cap of Acutaas Chemicals Ltd is 13,568 Cr..
What is the current Stock Price of Acutaas Chemicals Ltd as on 11 December 2025?
The current stock price of Acutaas Chemicals Ltd as on 11 December 2025 is 1,660.
What is the High / Low of Acutaas Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Acutaas Chemicals Ltd stocks is 1,902/919.
What is the Stock P/E of Acutaas Chemicals Ltd?
The Stock P/E of Acutaas Chemicals Ltd is 60.6.
What is the Book Value of Acutaas Chemicals Ltd?
The Book Value of Acutaas Chemicals Ltd is 173.
What is the Dividend Yield of Acutaas Chemicals Ltd?
The Dividend Yield of Acutaas Chemicals Ltd is 0.09 %.
What is the ROCE of Acutaas Chemicals Ltd?
The ROCE of Acutaas Chemicals Ltd is 19.9 %.
What is the ROE of Acutaas Chemicals Ltd?
The ROE of Acutaas Chemicals Ltd is 16.0 %.
What is the Face Value of Acutaas Chemicals Ltd?
The Face Value of Acutaas Chemicals Ltd is 5.00.